DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation

Ssu-Chuan Lai\textsuperscript{1,2}, Yu-Ting Su\textsuperscript{12,31}, Ching-Chi Chi\textsuperscript{4,51}, Yung-Che Kuo\textsuperscript{12,3}, Kam-Fai Lee\textsuperscript{6}, Yu-Chih Wu\textsuperscript{3,7}, Pei-Chi Lan\textsuperscript{3}, Muh-Hwa Yang\textsuperscript{8,9}, Te-Sheng Chang\textsuperscript{10,11} and Yen-Hua Huang\textsuperscript{12,2,3,12,13,14,15,16,17}

Abstract

Background: The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT4 expression and drug resistance. However, the underlying mechanism regarding the interplay between DNMTs and IL-6-induced OCT4 expression and the sorafenib resistance of HCC remains largely unclear.

Methods: HCC tissue samples were used to examine the association between DNMTs/OCT4 expression levels and clinical prognosis. Serum levels of IL-6 were detected using ELISA assays (n = 144). Gain- and loss-of-function experiments were performed in cell lines and mouse xenograft models to determine the underlying mechanism in vitro and in vivo.

Results: We demonstrate that levels of DNA methyltransferase 3 beta (DNMT3b) are significantly correlated with the OCT4 levels in HCC tissues (n = 144), and the OCT4 expression levels are positively associated with the serum IL-6 levels. Higher levels of IL-6, DNMT3b, or OCT4 predicted early HCC recurrence and poor prognosis. We show that IL-6/STAT3 activation increases DNMT3b/1 and OCT4 in HCC. Activated phospho-STAT3 (STAT-Y640F) significantly increased DNMT3b/OCT4, while dominant negative phospho-STAT3 (STAT-Y705F) was suppressive. Inhibiting DNMT3b with RNA interference or nanoamycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo. The fact that OCT4 regulates the DNMT1 expressions were further demonstrated either by OCT4 forced expression or DNMT1 silence. Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. Notably, targeting DNMT3b with nanoamycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells.

(Continued on next page)
Conclusions: The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC.

Keywords: Interleukin-6, Phospho-STAT3, OCT4, DNMT3b, Drug resistance, Hepatocellular carcinoma

Background
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is one of the leading causes of cancer mortality worldwide [1]. Chronic viral hepatitis infection contributes to the majority of HCC cases worldwide [2]. Despite advances in prevention and treatment strategies for this fatal disease, the incidence and mortality rate of HCC remain high, particularly for the Asian population [3]. With more surveillance of high risk patients, more HCC cases may be detected at an early stage when they are amenable to curative therapies [4]. Surgical resection is the most widely accepted therapy with a curative intention for the early stage HCCs [5]. However, the high tumor recurrence rate--up to 70% 5 years after surgery--remains a significant challenge. For advanced HCC, sorafenib is the first approved targeted therapy that yields statistically significant but clinically limited benefits as indicated by a 2–3 months increase in overall survival compared with placebo [6, 7]. Drug resistance to sorafenib has been the major obstacle for its clinical application in HCC. Multiple mechanisms, including crosstalk involving phosphoinositide-3-kinase–protein kinase B (PI3K/Akt) and Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling and the fibroblast growth factor 19/fibroblast growth factor receptor 4 (FGF19/FGFR4) axis, are attributable to sorafenib resistance [8–11]. In addition, epigenetic regulations, including histone modification, aberrant expression of miRNAs, and DNA methylation, are frequently involved in cancer stemness properties and drug resistance.

The expression of stemness-related genes, including octamer-binding transcription factor 4 (OCT4), stimulates a small population of cancer cells to gain the stemness-like properties that are responsible for the initiation and maintenance of primary tumors [12], and for tumor recurrence in some cancers, including HCC [13, 14]. Our previous study demonstrated that expression of the pluripotent transcription factor OCT4 is correlated with HCC recurrence, and is upregulated by interleukin-6 (IL-6) in a STAT3-dependent manner [14]. IL-6 is a prototypical cytokine which plays a pro-tumourogenic function in inflammation-associated cancers [15]. Constitutive activation of IL-6 signaling has been shown to establish a microenvironment for tumor initiation and progression [16]. In addition, IL-6 has been correlated with tumor stage and cancer stem cell (CSC)-like properties in human HCC [17, 18].

OCT4 is expressed in embryonic stem cells, germ cells, and various human cancers [19–22]. It is known to be a master regulator of stem cell pluripotency and self-renewal [23]. Emerging evidence has shown a correlation between OCT4 expression and tumor initiation and CSC-like phenotypes in many cancers, including prostate cancer, melanoma, and HCC [24–26]. OCT4 is also considered to be one of the most critical epigenetic mediators [27, 28]. Several epigenetic modifications, including DNA methylation, chromatin remodeling and long non-coding RNAs, have been implicated in the regulation of OCT4 gene expression [21, 29, 30].

DNA methylation, the transfer of methyl groups to DNA molecules catalyzed by DNA methyltransferases (DNMTs), occurs almost exclusively in CpG islands in mammals. Non-CpG methylation occurs in embryonic stem cells and has recently been observed during human B cell differentiation [21, 31]. The DNMT family includes DNMT1, DNMT3a, and DNMT3b. DNMT1 has been shown to maintain methylation in somatic cells, and DNMT3a and DNMT3b are thought to be involved in de novo DNA methylation in embryonic stem cells and early embryos. It was recently found that DNMT1, DNMT3a, and DNMT3b are overexpressed in several human tumors, compared to levels in corresponding normal tissues [32–34]. Numerous studies have indicated that these DNMTs are associated with hepatocarcinogenesis [14, 33–38]. Chronic HBV infection has been shown to significantly stimulate the up-regulation of DNMT1, DNMT3a, and DNMT3b in tumors that were associated with HCC progression [36]. HBV infection has also been shown to be highly correlated with increases in IL-6 [39], and we have previously demonstrated that increases in IL-6 can stimulate OCT4 expression through IGF-1R in HBV-related HCC (HBV-HCC) [14]. However, the underlying mechanism linking IL-6, OCT4, and DNMTs with sorafenib resistance in HCC remains largely unknown.

This study demonstrates that activation of IL-6/STAT3 regulates OCT4 expression through DNMT3b, which is an indicator of early tumor recurrence and poor prognosis.
of HCC. DNMT3b inhibitor nanaomycin A showed a synergistic effect with sorafenib in the sorafenib resistant Hep3B cells. Findings from this study highlight the significance of IL-6-DNMT3b–mediated signaling as a potential therapeutic target for patients with HCC exhibiting cancer stemness-related properties and sorafenib resistance.

**Methods**

**Cell lines**
The Hep3B (HBV+ HBsAg+ human HCC, HB-8064) and HepG2 (HBV+ human hepatoblastoma, HB-8065) cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The Huh7 (HBV+ human HCC) cells were obtained from the Japanese Collection of Research Bioresources. The HepG2.2.15(HBV+ HBsAg+ human hepatoblastoma) cells were kindly provided by Dr. Jun-Jen Liu (School of Medical Laboratory Science and Biotechnology, College of MedicalScience and Technology, Taipei Medical University, Taipei, Taiwan). Mycoplasma-free cell lines were used in all of our experiments. The sorafenib-resistant cells (sorafenib-resistant Hep3B or HepG2.2.15 cells) were generated by treating the cells with low dose sorafenib (1 nM) in the beginning, followed by a 10% increase in the sorafenib concentration every week until the maximum tolerated doses had been reached [40]. All the cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco-BRL, Thermo Fisher Scientific Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) and 3.7 g/L sodium bicarbonate (Sigma-Aldrich), penicillin streptomycin (PS) (Gibco), and 1% glutamax (Gibco). For the IL-6 treatment, cells in serum-free media were treated with 50 ng/mL IL-6 (Peprotech, USA).

**HCC tissues**
Human frozen HCC tissues and sera were obtained from 144 patients who had received curative hepatectomy between 2004 and 2013 at Chang Gung Memorial Hospital, Chiayi, Taiwan (Additional file 1: Figure S1). This study was approved by the Institutional Review Board of Chang Gung Medical Foundation (Approval number: 101–3575B).

**Serum IL-6 ELISA assay**
Concentrations of serum IL-6 from the HCC patients (n = 144) were determined using an ELISA assay for human IL-6 (Bio Legend, San Diego, CA, USA) according to the manufacturer’s instructions.

**RNA isolation and real-time reverse-transcription polymerase chain reaction**
Cell lines and frozen HCC tissues were subjected to total RNA isolation and quantitative real-time reverse-transcription polymerase chain reaction (RT-qPCR). For cell lines, total RNA was extracted with the Easy Pure Total RNA Spin Kit (Bioman, Taipei, Taiwan) according to the manufacturer’s instructions. Frozen tissues were homogenized in liquid N2 and lysed in RNA extraction buffer. The cDNA synthesis was performed using random primers (Invitrogen, Carlsbad, CA, USA) and MMLV reverse transcriptase (Invitrogen) according to the manufacturer’s instructions. The RT-qPCR amplification was performed with the LightCycler® 480 SYBR Green I Master (Hoffman-La Roche, Basel, Switzerland). The primer sequences, annealing temperatures, and PCR cycling conditions are described in Additional file 1: Table S1. The beta-2 M was used as an internal control.

**Immunoblotting and antibodies**
Human HCC cell lines were extracted using lysis buffer containing 1% TritonX-100, 150 mM NaCl, 1 mM EDTA and 10 mM Tris-HCl (pH 7.5) with a protease inhibitor cocktail (Roche Diagnostics, NA, USA). Protein concentration was measured by the bicinchoninic acid (BCA) assay (Pierce, Rockford IL, USA). Equal amounts of protein were separated through 8% or 10% SDS-PAGE, transferred to a PVDF membrane, and subsequently probed using primary antibodies (Additional file 1: Table S2) at 4 °C overnight. Horseradish peroxidase (HRP)-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) were used and the immunoreactive bands were visualized using the enhanced chemiluminescence system (Amersham Pharmacia Biotech, Buckinghamshire, UK).

**Short hairpin RNA and plasmids**
The packaging pCMVΔR8.91 plasmid and the envelope VSV-G pMD.G plasmid were co-transfected with shDNMT3b#1 (TRCN0000035686, Taiwan RNAi consortium, Taipei, Taiwan), shDNMT3b#2 (TRCN0000035685), shDNMT1#1 (TRCN0000232749), shDNMT1#2 (TRCN0000021893), or shCtrl. (TRCN0000072260) plasmids into HEK293T cells using Turbofect transfection reagent according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA). STAT3-WT, STAT3-Y640F and STAT3-Y705F plasmids were kindly provide by Prof. Muh-Hwa Yang (National Yang-Ming University, Taipei, Taiwan). The pMXs-OCT4 plasmids were provided by Dr. Hung-Chih Kuo (Academia Sinica, Taipei, Taiwan).

**Aldehyde dehydrogenase (ALDH) activity assay**
ALDH enzymatic activity was measured using an ALDEFLUOR™ assay kit (Stemcell Tech, Grenoble, France) and a fluorescence-activated cell sorting Calibur system (BD Biosciences, San Jose, CA, USA) according to the manufacturer’s manual instructions. Briefly, the cells were harvested and re-suspended in ALDEFLUOR™ assay buffer containing an ALDH substrates (1 μM per
1 × 10^6 cells) at 37 °C for 60 min. For a negative control in each experiment, a sample of cells was incubated, under identical experimental conditions, with 50 mM of the specific ALDH inhibitor diethylaminobenzaldehyde (DEAB).

Tumor xenograft mouse model
Female 8-week-old athymic nude mice (BALB/cAnN. Cg-Foxn1nu/CrlNarl) were obtained from the National Laboratory Animal Center and National Applied Research Laboratories (Taipei, Taiwan). The animal study protocol was approved by the Institutional Animal Care and Use Committee/Panel at Taipei Medical University, Taipei, Taiwan.

The mice were subcutaneously inoculated with Hep3B (5 × 10^6 cells) in the left flank, then injected with PBS or IL-6 (200 ng) at the implantation site every 3 days. Tumor volumes, calculated as 0.5 × length × width^2 (mm^3), were measured at one-week intervals over 56 days. The tumor tissues were collected at week eight post-implantation.

For nanaomycin A experiments, female eight-week-old NOD-SCID mice (National Laboratory Animal center) were subcutaneously inoculated with Hep3B (5 × 10^6 cells) in the left flank, and locally injected with IL-6 (200 ng) at 3 day internals over 12 weeks. The mice were then divided into three groups: control DMSO group (n = 6), low dose nanaomycin A (2 μM, n = 6), and high dose nanaomycin A (20 μM, n = 6). The mice were treated with either DMSO or nanaomycin A every two days for a two week period. All the mice were sacrificed at week 14 and analyzed by immunohistochemical staining assays against the DNMTs and OCT4.

Immunohistochemical staining
Matched pairs of paraﬁn-embedded HCC samples and adjacent liver tissues from patients receiving hepatectomy for HCC were used to construct the tissue microarray [41]. To produce the TMA block, tissue cylinders (1.5 mm in diameter) were punched from the region of the donor block and were transferred to an 18 × 30 mm paraffin block with the use of an automatic tissue arrayer instrument (Autotiss 1000, Ever BioTechnology, Canada). Formalin-fixed, paraffin-embedded human TMA blocks or mice tissue blocks were cut into 5-μm-thick continuous sections and mounted on poly-L-lysine-coated glass slides. After deparafﬁnization using xylene, slides were rehydrated in graded alcohol washes, washed in tap water and heated in 0.01 M citric buffer (pH 6.0) for 10 min with autoclaving. After cooling, the slides were treated with 3% H2O2 in phosphate buffered saline (PBS) at room temperature for 30 min, washed with PBS, blocked with 0.5% triton X and 5% normal horse serum in PBS and then incubated with primary antibodies (Additional file 1: Table S2) at 4 °C overnight, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies and detected using 3,3′-diaminobenzidine tetrachloride (DAB) as the chromogen (DakoCytomation, Carpentaria, CA, USA). The immune-stained sections were counterstained with hematoxylin, dehydrated and mounted. Sections were then quantitatively analyzed using the Image Scope software (Aperio Technologies, Vista, CA, USA). The positive staining intensities of p-STAT3, DNMT1, DNMT3a, DNMT3b, and OCT have been presented as the total intensity per total pixels. Three randomly selected high-power ﬁelds were analyzed for each tumor section.

Transwell assay
Transwell assays were performed using 8-μm pore transwell chambers in 24-well plates (Corning Costar, Cambridge, MA, USA). The upper chambers were seeded with 1 × 10^5 Hep3B cells in 100 uL of the serum-free DMEM/F12 medium. The lower chambers were ﬁlled with 800 uL of the DMEM/F12 medium containing 10% FBS. Subsequently, the cells were incubated at 37 °C in a 5% CO2 humidified atmosphere for 24 h. The cells were treated with nanaomycin A in dose dependently. 48 h later, cells in the top side of the chamber was removed and cells in the bottom side of the chambers were ﬁxed in 95% alcohol for 30 min, and then stained with crystal violet. The number of cells per three randomly selected ﬁelds was counted under the microscope (Olympus, Tokyo, Japan).

Cell viability assay
For the proliferation assay, the naïve or sorafenib-resistant Hep3B/HepG2.2.15 cells were seeded in 96-well plates at 10^4 cells/well and incubated at 37 °C in 5% CO2 for 48 h. For the drug sensitivity assay, the cells were seeded for 24 h and treated with various concentrations of sorafenib (#8705 Cell Signaling), or liposomal doxorubicin (Lipo-DOX, TTY Biopharm Company Limited, Taiwan), and these cells were then incubated at 37 °C in 5% CO2 for 48 h. Thereafter, a WST-1 assay (Roche) was used to detect cell proliferation according to the manufacturer’s instructions. Three experiments were performed for each experimental condition. Cell viability is expressed as the percentage of non-treated cells.

The drug combination index (CI)
The effects of drug combinations were evaluated using Chou–Talalay median effect analysis. Cells were treated with single drug alone or in combination. The cell proliferation was measured using WST-1 assay, and the drug combination index (CI) was examined by the Chou–Talalay method. The CI values of <0.9 were considered as evidence of synergy; 0.9–1.1 of additive effects; and CI > 1.1 of antagonism.
Statistical analysis
Data are presented as mean ± standard deviation (SD) or median (standard error of mean [SEM]), as appropriate. The statistical differences in the means were assessed using the unpaired student’s t test and one-way analysis of variance [18], or Spearman’s correlation analysis (GraphPad Software, La Jolla, CA, USA) for all cases.

Results
The positive correlation between serum IL-6 levels, DNMT3b/1 expression, and OCT4 expression with poor prognosis of human HCC
IL-6 has been associated with the expression of genes that contribute to stemness properties in HCC [13–15]. IL-6 has also been shown to upregulate DNA methyltransferase in several cancers [42–44]. To investigate the associations between serum IL-6 levels and OCT4 and DNMT mRNA in human HCC tissues, serum IL-6 levels from 144 HCC patients were compared with OCT4 and DNMT mRNA levels from paired frozen tumor tissue (T) and adjacent peritumor tissue (PT) samples (Table 1 and Additional file 1: Figure S1) using ELISA and real-time qRT-PCR. The expression levels (either high [T/PT ≥ 2] or low [T/PT < 2]) of OCT4, DNMT3b, and DNMT1 were assessed. As shown in Fig. 1, we found that patients with high serum IL-6 levels showed a poorer overall survival (OS) compared with patients with low IL-6 levels (Fig. 1a, P = 0.007), and had more early tumor recurrence (Fig. 1b, P = 0.0004 for IL-6 and Table 1, n = 144). HCC patients who displayed higher levels of OCT4 also had significantly higher levels of serum IL-6 (Fig. 1c). The patients who expressed both higher serum IL-6 and OCT4 were more likely to have HBV-HCC than hepatitis C (HCV)-HCC (Additional file 1: Figure S2). We also observed significant positive correlations between OCT4 expression levels and DNMT3b (Fig. 1d, R = 0.7253, P < 0.0001) and between OCT4 and DNMT1 (Fig. 1e, R = 0.4471, P < 0.0001). HCC patients who displayed higher levels of OCT4 also had significantly higher levels of DNMT3b (Fig. 1f, P < 0.0001), and these patients with higher expression levels of OCT4 (P = 0.005) and DNMT3b (P = 0.0217) had significantly higher rates of tumor recurrence (over 120 months), and of early recurrence (within 24 months) (Fig. 1g). In contrast, the correlation between OCT4 and DNMT3a was relatively weak (Additional file 1: Figure S3).

The clinical relevance of OCT4, DNMT3b and DNMT1 expression levels in HCC prognosis was further examined using The Cancer Genome Atlas (TCGA) database and Kaplan–Meier analysis [45, 46]. As shown in Fig. 1h, Kaplan–Meier analysis showed that higher expression of DNMTs was associated with a trend for poor OS (P = 0.0081 for DNMT3b; P = 0.0045 for DNMT1; P = 0.02 for DNMT3a). These results were further supported by the other TCGA-PanCancer Atlas datasets from the cBioPortal for Cancer Genomics. Gene expression across these datasets revealed significantly higher expression levels of DNMT3b, OCT4, and DNMT1 in the primary tumors compared with the normal tissues (Additional file 1: Figure S4a, b and c). In addition, there was a significant positive correlation between the gene expression levels of OCT4 with DNMT3b (Additional file 1: Figure S4d, R = 0.2523, P < 0.0001) and DNMT1 (Additional file 1: Figure S4e, R = 0.2121, P < 0.0001). Although the DNMT3a level in tumor tissues was higher than that of the normal tissues, there was no statistical significance between the expression levels of OCT4 and DNMT3a in tumors (Additional file 1: Figure S4f and g).

The protein expressions of DNMT3b, OCT4, and DNMT1 in HCC tissues were also examined by immunohistochemical staining (Fig. 1i). Taken together, these results strongly suggest that the levels of IL-6, DNMT3b/1, and OCT4 are highly correlated and that they play a role in early tumor recurrence and poor prognosis of HCC patients.

IL-6 activates the expression of DNMT3b, OCT4, and DNMT1 in Hep3B cells in vitro and in vivo
HCC patients with virus infection have been shown to have high expression of IL-6 [14]. As we found a positive correlation between serum IL-6 levels and OCT4 expression in HCC (Fig. 1c), we next examined the effect of IL-6 on expression levels of OCT4 and DNMTs in HCC cells. Human HCC cell lines that contain the HBV genome (Hep3B and HepG2.2.15) or do not contain the HBV genome (HepG2 and Huh7) were used in this experiment, and the mRNA levels of DNMTs and OCT4 were detected using qPCR. As shown in Fig. 2a, IL-6 treatment significantly increased OCT4 and DNMTs mRNA expression, particularly in HBV”HBsAg” Hep3B and HepG2.2.15 cells. Western blotting results further demonstrated that IL-6 significantly increased the protein expression of DNMT3b, OCT4, and DNMT1 in HBV”HBsAg” Hep3B and HepG2.2.15 cells, but not in HBV”HBsAg” HepG2 and Huh7 cells (Fig. 2b). The quantitative analytic results are shown in Fig. 2c.

Further experiments using a xenograft animal model confirmed that IL-6/p-STAT3 activation increased the expression of DNMT3b, OCT4 and DNMT1, and, to a much lesser extent, of DNMT3a, in Hep3B-derived tumors in vivo (n = 12). When compared to the PBS control group, immunohistochemical staining showed that IL-6 treatment dramatically increased p-STAT3 protein levels, and markedly increased the expression of OCT4, DNMT3b, and DNMT1 in Hep3B tumors (Fig. 2d). These results demonstrate that IL-6/p-STAT3 activates the expression of DNMT3b, OCT4, and DNMT1 in Hep3B both in vitro and in vivo.
P-STAT3 activation enhances the expression of DNMTs and OCT4 and increases ALDH activity in human Hep3B cells

To confirm the role of STAT3 signaling in the expression of DNMT and OCT4 in HCC cells, plasmids with constitutively activated p-STAT3 (STAT3-Y640F) and dominant negative p-STAT3 (DN STAT3-Y705F) were employed. We found that constitutively activated p-STAT3 (STAT3-Y640F) significantly increased the expressions of DNMT3b, OCT4, and DNMT1 in Hep3B cells compared with those in wild-type STAT3, whereas DN STAT3-Y705F exhibited a suppressive effect (Fig. 3a). The quantitation assay is presented in Fig. 3b.

To identify the specific DNMT that was responsible for the p-STAT3-induced stemness-related ALDH activity and the increased OCT4 expression, RNA interference experiments were conducted targeting DNMT3b (short hairpin [sh]DNMT3b) or DNMT1 (shDNMT1) in STAT3-Y640F Hep3B cells. Activated phospho-STAT3 (STAT3-Y640F) significantly enhanced the ALDH activity

---

**Table 1** Variables associated with early tumor recurrence after hepatectomy for HCC (N = 144)

| Variable                              | Recurrence \(^a\) | Univariate analysis | Multivariate analysis | P value | Hazard ratio | 95% confidence interval |
|---------------------------------------|------------------|--------------------|-----------------------|---------|--------------|------------------------|
|                                       |                  | P value            |                       |         |              |                        |
| Gender (male vs. female)              | 0.154            | –                  | –                     | –       | –            |                        |
| Age, years (< 55 vs. ≥ 55)            | 0.707            | –                  | –                     | –       | –            |                        |
| HBV (yes vs. no)                      | 0.540            | –                  | –                     | –       | –            |                        |
| HCV (yes vs. no)                      | 0.647            | –                  | –                     | –       | –            |                        |
| Bilirubin, mg/dL (< 1.2 vs. ≥ 1.2)    | 0.863            | –                  | –                     | –       | –            |                        |
| Albumin, g/dL (< 3.5 vs. ≥ 3.5)       | 0.252            | –                  | –                     | –       | –            |                        |
| ALT, U/L (< 35 vs. ≥ 35)              | 0.207            | –                  | –                     | –       | –            |                        |
| PT, INR (< 1.2 vs. ≥ 1.2)             | 0.075            | 0.104              | 2.827                 | 0.808–9.885 |              |                        |
| ICG, retention rate (< 15% vs. ≥ 15%) | 0.170            | –                  | –                     | –       | –            |                        |
| TNM stage (T1/2 vs. T3/4)             | 0.417            | –                  | –                     | –       | –            |                        |
| Multiple tumors (yes vs. no)          | 0.739            | –                  | –                     | –       | –            |                        |
| Child-Pugh class (A vs. B)            | 0.251            | –                  | –                     | –       | –            |                        |
| Complete tumor capsule (yes vs. no)   | 0.051            | 0.081              | 0.418                 | 0.157–1.112 |              |                        |
| Microvascular invasion (yes vs. no)   | 0.001\(^b\)     | 0.398              | 1.468                 | 0.603–3.578 |              |                        |
| Macrovacular invasion (yes vs. no)    | < 0.001\(^b\)   | 0.002\(^b\)       | 11.993                | 2.553–56.339 |              |                        |
| Cut margin free (yes vs. no)          | 0.873            | –                  | –                     | –       | –            |                        |
| Differentiation grade (1/2 vs. 3/4)   | 0.168            | –                  | –                     | –       | –            |                        |
| Tumor size, cm (< 3 vs. ≥ 3)          | 0.039\(^b\)     | 0.554              | 0.788                 | 0.359–1.733 |              |                        |
| Satellite nodules (yes vs. no)        | 0.008\(^b\)     | 0.969              | 1.019                 | 0.393–2.640 |              |                        |
| AFP, ng/mL (< 400 vs. ≥400)           | 0.625            | –                  | –                     | –       | –            |                        |
| Serum IL-6, ng/mL (< 150 vs. ≥ 150)   | 0.023\(^b\)     | 0.088              | 1.896                 | 0.910–3.949 |              |                        |
| Serum TGF-β (< 14,000 vs. ≥ 14,000)   | 0.682            | –                  | –                     | –       | –            |                        |
| DNMT1 (< 2X vs. ≥ 2X)                 | 0.010\(^b\)     | 0.719              | 1.144                 | 0.550–2.378 |              |                        |
| DNMT3a (< 2X vs. ≥ 2X)                | 0.305            | 0.239              | 1.632                 | 0.722–3.689 |              |                        |
| DNMT3b (< 2X vs. ≥ 2X)                | 0.037\(^b\)     | 0.199              | 1.779                 | 0.739–4.285 |              |                        |
| OCT4 (< 2X vs. ≥ 2X)                  | 0.026\(^b\)     | 0.085              | 1.990                 | 0.909–4.357 |              |                        |
| NAMOG (< 2X vs. ≥ 2X)                 | 0.004\(^b\)     | 0.010\(^b\)       | 3.074                 | 1.309–7.220 |              |                        |
| High expression of OCT4 and DNMT3b (< 2X vs. ≥ 2X) | 0.001\(^b\) | 0.395              | 1.484                 | 0.597–3.685 |              |                        |
| High expression of OCT4 and DNMT1 (< 2X vs. ≥ 2X) | 0.013\(^b\) | 0.226              | 1.754                 | 0.705–4.364 |              |                        |

* Abbreviations: AFP serum α-fetoprotein, ALT alanine aminotransferase, ICG indocyanine green, PT prothrombin time, INR international normalized ratio, Tumor size, the largest one if multiple

*Time to early recurrence (less than 2 years)

\(^b\)P < 0.05.
Fig. 1 (See legend on next page.)
To examine if targeting DNMT3b could effectively suppress the STAT3-Y640F-induced ALDH activity (Fig. 3c and d) and the expressions of DNMT3b, OCT4, and DNMT1 (Fig. 3e and f). By contrast, DNMT1 knockdown exhibited less effect on the STAT3-Y640F-induced ALDH activity (Fig. 3c and d) and OCT4 expression (Fig. 3e and f). These results demonstrated that the epigenetic regulator DNMT3b regulated the p-STAT3-induced ALDH activity and OCT4 expression in Hep3B cells.

**IL-6 increases OCT4 expression through a DNMT3b-OCT4-DNMT1 axis**

To further examine whether the IL-6 regulates the OCT4 expression through a DNMT3b-OCT4-DNMT1 pathway, RNA interference experiments using shDNMT in Hep3B cells with and without IL-6 treatment were performed. The results revealed that IL-6 effectively increased the expression of DNMT3b and OCT4, and shDNMT3b (Clone #1) effectively suppressed the effect of IL-6 (Fig. 4a and Additional file 1: Figure S5). To further confirm the effect of DNMT3b on OCT4 expression, two effective shDNMT3b clones (Clone #1 and #2) were used in the experiments. We found that DNMT3b silencing significantly suppressed the OCT4 expression, and to a less extent, of DNMT1 (Fig. 4b). Forced expression of OCT4 significantly increased the cell viability (Additional file 1: Figure S6) and the DNMT1 expression, but had no effect on the DNMT3b or DNMT3a expression in Hep3B cells (Fig. 4c). By contrast, DNMT1 knockdown (shDNMT1 clone #1 and #2) did not exhibit any effect on the DNMT3b or OCT4 expression (Fig. 4d). These results demonstrated that IL-6 regulated the OCT4 expression through the DNMT3b-OCT4-DNMT1 axis in HCC.

**DNMT3b inhibitor suppresses IL-6-induced OCT4 expression and tumorigenicity in xenografted Hep3B tumors in NOD-SCID mice**

To examine if targeting DNMT3b could effectively suppress OCT4 expression, the DNMT3b-selective inhibitor nanaomycin A [47], a unique quinone antibiotic isolated from *Streptomyces* that induces genomic demethylation, was used. As shown in Fig. 5, we found that the nanaomycin A treatment decreased the basal protein levels of DNMT3b, OCT4, and N-cadherin (Fig. 5a) and the cell migration ability (Fig. 5b) of Hep3B cells in a dose-dependent manner. The low dose of nanaomycin (1 μM) can suppress the DNMT3b/OCT4 levels and cell migration ability more than 50%. IL-6 was able to induce protein expression of DNMT3b/1 and OCT4, and the nanaomycin A (20 μM) effectively suppressed the IL-6-induced expression of DNMT3b, OCT4, and DNMT1 (Fig. 5c).

The effect of nanaomycin A on DNMT expression in vivo was further examined using a xenograft NOD-SCID tumor model. NOD-SCID mice were subcutaneously inoculated with Hep3B, and then received local IL-6 treatment (200 ng/mouse/3 days) over a course of 12 weeks (Fig. 5d). After 12 weeks, the mice were divided into three groups based on nanaomycin A treatment. The immunostaining analysis showed that IL-6 effectively increased p-STAT3, STAT3, DNMT3b/1, and OCT4 expression in Hep3B-derived tumors, and that nanaomycin A significantly suppressed the effect of IL-6 in a dose-dependent fashion (Fig. 5e). The quantitative analytic results are shown in Fig. 5f. These results demonstrate that DNMT3b regulates the IL-6-induced expression of OCT4 in HCC both in vitro and in vivo.

**DNMT3b inhibitor increases the drug sensitivity of sorafenib-resistant HCC cells**

To examine the role of DNMT3b in sorafenib resistance in HCC, the sorafenib-resistant Hep3B cells were generated in medium with increasing of sorafenib concentration stepwisely. When compared with the naïve cells, the sorafenib-resistant HCC cells showed a higher value of IC50 (15.76 μM vs. 9.52 μM) (Fig. 6a), and expressed higher levels of *IL-6R*, *DNMT3b* and stemness-related genes (Fig. 6b and Additional file 1: Figure S7). Inhibition of DNMT3b by nanaomycin A significantly increased the sorafenib sensitivity in a dose-dependent manner (Fig. 6c).
Fig. 2 IL-6 activates the expression of DNMTs and OCT4 in vitro and in vivo. 

a. The effect of IL-6 (50 ng/mL) on mRNA expression of DNMTs and OCT4 in HBV+HBsAg+ HCCs (Hep3B and HepG2.2.15) and HBV−HBsAg− HCCs (HepG2) under different incubation time assessed by real-time qPCR.

b. The effect of IL-6 (50 ng/mL) on the protein expression of DNMTs and OCT4 in HBV+HBsAg+ HCCs (Hep3B and HepG2.2.15) and HBV−HBsAg− HCCs (HepG2 and Huh7) by western blotting. The qualitative data is shown in (c). Three individual experiments were carried out for each experimental condition. *P < 0.05, **P < 0.01, ***P < 0.0001, student t test.

c. Xenografts of 5 × 10^6 Hep3B cells in athymic nude mice with IL-6 (200 ng/mouse/3 d) treatment (n = 6). Immuno-histochemical staining for p-STAT3, DNMT3b, OCT4, DNMT1, DNMT3a, and the control IgG are shown (Bar, 100 μm)
and d). The similar effect of nanaomycin A on lipo-DOX sensitivity was also shown (Additional file 1: Figure S8). The synergistic effect of nanaomycin A and sorafenib on the suppression of sorafenib-resistant Hep3B proliferation were shown in Fig. 6e and Table 2. These results demonstrate that targeting DNMT3b with nanaomycin A
showed a synergistic effect with sorafenib in the treatment of sorafenib-resistant HCC. The results revealed that DNMT3b was involved in the IL-6-induced OCT4 expression axis in sorafenib-resistant Hep3B cells.

**Discussion**

The inflammatory cytokine IL-6 is known to be involved in the pathogenesis and progression of various cancers. IL-6 has been shown to increase cancer stemness-related
Fig. 5 (See legend on next page.)
upregulate DNMTs in HCCs associated with poor outcomes. Recent studies have suggested that both HBV and HCV infection can induce cell proliferation via STAT3 dependent upregulation of DNMT1 and DNMT3b axis in cell proliferation and epithelial-mesenchymal transition (EMT) and poor cancer prognosis was observed. In oral cancer, a role for an IL-6-DNMT3b axis has been known to induce chronic systemic inflammation [14]. Our previous study demonstrated that HBV-derived niche IL-6 can upregulate OCT4 expression through insulin-like growth factor 1 receptor (IGF-1R) signaling and the OCT4 expression can result in early tumor recurrence [14].

We have previously demonstrated the positive correlation of another pluripotent transcription factor, NANOG, with IGF-1R activation (phospho-IGF-1R) in HCC tissues, and showed that IGF-1/IGF-1R activation regulates NANOG expression in HCC in vitro and in vivo [14]. In addition, the IGF-1R signaling was demonstrated to regulate NANOG, which controls CSC self-renewal and maintains CSC-related properties in HCC [55]. In this study, we found that DNMT3b was positively correlated with NANOG (R = 0.7330, P < 0.0001) and IGF-1R (R = 0.5419, P < 0.0001) in HCC tissues (Additional file 1: Figure S10a and b). No significant correlation between DNMT1 and NANOG or IGF-1R was observed (Additional file 1: Figure S10c and d).

Constitutively active STAT3 signaling has been documented in human cancers including HCC and oral cancer [17, 42]. Factors involving inflammatory cytokines, growth factors and virus infection have been shown to activate hepatic STAT3 signaling [14, 17]. However, the roles of IL-6, DNMTs, and OCT4 in HCC still remain unclear. In oral cancer, a role for an IL-6-DNMT3b axis in cell proliferation and epithelial-mesenchymal transition (EMT) and poor cancer prognosis was observed [42]. But, the relationship between IL-6-DNMT3b and OCT4 expression was not discussed in this literature [42]. Liu et al. showed that IL-6 enriched lung cancer stem-like cell populations by the inhibition of cell cycle regulators via DNMT1 upregulation [48]. However, the role of IL-6 in the regulation of DNMT3b was not addressed. Recently, Quan et al. suggested that IL-6 can induce cell proliferation via STAT3 dependent upregulation of DNMT1 and DNMT3b in renal cell carcinoma [50]. However, OCT4 was not examined in that study [50]. Advancing these previous findings and extending our previous study, which showed that IL-6/STAT-3 upregulates OCT4 through IGF-1R [14], the current
Fig. 6 (See legend on next page.)
work demonstrates that the IL-6-STAT3 signaling drives OCT4 expression through the regulation of DNMT3b in HCC (Fig. 7).

IL-6, DNMTs and cancer stemness-related genes like OCT4 usually interplay with one another to promote carcinogenesis. Kaplan-Meier analysis of our patients showed that DNMT3b and OCT4 gene expression levels were positively correlated with tumor recurrence (Fig. 1g). HCC is well known for its marked genetic heterogeneity, which remains a major obstacle in attempts to develop an effective therapy [56]. The IL-6-STAT3 mediated IGF-1/IGF-1R signaling or DNMT3b-OCT4-DNMT1 regulation in HCC may be two of the multiple factors involved in stemness expression and tumor recurrence. These observations strongly suggest that the overall outcome of HCC may depend not only on blocking the IGF-1R/OCT4 pathways, but also other complementary and/or synergistic factors like IL-6 and DNMT3b.

The promoter region of the OCT4 gene is typically hypermethylated in somatic cells such as those in the liver [21], thus it is likely that there are other mediators between DNMT3b and OCT4 not yet delineated in our study. It is well known that microRNAs (miRNAs) are involved in diverse biological processes, such as cell proliferation, tumorigenesis, apoptosis, invasion, and angiogenesis of cancer cells [57]. miRNAs are important for the regulation of cancer stem-like properites [58]. A previous study revealed that miR-335 negatively regulates osteosarcoma stem-like properites [59]. Further, stem cell-related genes OCT4 and SOX2 are among the target genes regulated by miR-145, suggesting that miR-145 may play an important role in the maintenance of cancer stem cells [60]. Moreover, miR-145 was shown to play an oncogenic role in hepatocarcinogenesis [22]. Through software predictions and with support from previous studies, we propose that miR-145 may regulate OCT4 expression through DNMT3b.

Sorafenib is the first FDA-approved targeted therapy for patients with advanced HCC. However, the sorafenib has a number of disabling side effects [61], and its efficacy has not been satisfied. Currently many attempts in combining with other agents to minimize the sorafenib dose have been reported, including the epigenetic therapeutics [62]. Liu et al., showed that DNMT1 was upregulated through STAT3 signaling pathway in the sorafenib-resistant non HBV/HCV-infected HepG2 and Huh7 cells. Blocking DNMT1 by their inhibitor can decrease colony formation and enhanced sorafenib sensitivity in HCC cells resistant to sorafenib [63]. Besides, in hormone refractory prostate cancers, the tumor cells presented drug resistance and increased the expressions of DNMT1 and DNMT3b. Down-regulating of the DNMT1 and DNMT3b activity by DNMT inhibitor acacytidine results in the increase of the drug sensitivity in cells [64].

Different from the Liu’s study in HCC, our results demonstrated that the combination of sorafenib and the low dose nanaomycin A (2 µM), which specific inhibit the DNMT3b can synergistically suppressed the proliferation of sorafenib-resistant HBV’Hep3B cells (Fig. 6de). The fact that low dose nanaomycin A did not suppress DNMT1 expression in Hep3B cells (Fig. 5a), indicates that the role of DNMT3b is specific in HBV’Hep3B cells, and the differential DNMT expression patterns in HCCs of different etiologies would be the critical factors. Our results demonstrated that targeting DNMT3b would increase the sorafenib sensitivity and augment the therapeutic effect of sorafenib on sorafenib-resistant HCC cells, in particular for the HBV-HCC.

### Table 2
IC50 of Sorafenib and nanaomycin in Hep3B naïve cells and Hep3B resistant cells

| Drugs (µM) | Hep3B naïve cells | Hep3B resistant cells |
|-----------|-------------------|-----------------------|
| Sorafenib | 9.56 ± 1.77       | 15.7 ± 3.11           |
| Nanaomycin| 5.56 ± 3.19       | 7.48 ± 5.92           |
| Sorafenib + Nanaomycin 2 | 6.38 ± 0.81 | 7.71 ± 0.88 |
| Sorafenib + Nanaomycin 5 | 3.01 ± 0.75 | 4.68 ± 0.95 |
| Sorafenib + Nanaomycin 10 | 1.42 ± 0.20 | 2.06 ± 0.43 |

**Conclusions**

In summary, the current study demonstrated that the DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of HCC through IL-6/p-STAT-3 regulation. The mechanism of IL-6/p-STAT-3 signaling in the sequential activation signaling of the DNMT3b-OCT4-DNMT1 axis in HCC was successfully delineated.
Targeting DNMT3b showed a synergistic effect with sorafenib in the treatment of the sorafenib resistant HCCs (Fig. 7). The results of this study could provide therapeutic strategies for the HCC patients expressing cancer stemness properties such as DNMT3b/OCT4 expression and/or sorafenib resistance.

Additional file

Additional file 1. Supplementary information.

Abbreviations
CSC: Cancer stem cell; DNMT: DNA methyltransferase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; IL-6: Interleukin-6; Lipo-DOX: Liposomal doxorubicin; OCT4: Octamer-binding transcription factor4; STAT: Signal transducer and activator of transcription; TCGA: The Cancer Genome Atlas

Acknowledgments
We thank the Tissue Bank (Chang Gung Memorial Hospital, Chiayi, Taiwan) for providing the HCC tissue and CGMH Core Facility Center for providing high-quality tissue microarrays. Thanks to Mr. Ting-Hao Wang (TissueFAXS and Histoquest) of TMU Core Facility Center (Taipei Medical University) for his excellent technical support.

Authors’ contributions
Conception and design: SCL, TSC, MHY and YHH; Development of methodology: SCL, YTS, TSC, YCW, YCK, PCL and YHH; Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): SCL, YTS, TSC, CCC, KFL, YHH; Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): SCL, YTS, TSC, MHY, YHH; Writing, review, and/or revision of the manuscript: SCL, TSC, MHY, YHH. All authors have read and approved the final manuscript.

Funding
This study is supported by research grants from Ministry of Science and Technology, Taiwan (Grant numbers: MOST105–2628-B-038-008-MY3, MOST106–3114-B-038-001, MOST107–2321-B-038-002, MOST107–2314-B-038-057, MOST107–2314-B-038-061, MOST108–2314-B-038-006, MOST108–2320-B–038–023-MY3, and MOST108–2321-B–038-003); Health and Welfare Surcharge of Tobacco Products (Grant numbers: MOHW103-TD-B–111-01, MOHW104-TDU-B–212-124-001, MOHW105-TDU-B–212-134001, MOHW106-TDU-B–212-144001, MOHW107-TDU-B–212-114014, and MOHW108-TDU-B–212-124014); Ministry of Education, Taiwan (Grant numbers: DP2–107–21212–01–T02, DP2–108–21212–01–T02–02; Chang Gung Memorial Hospital (CORPGF0053 and CMRPGF0163); Taipei Medical University (Grant numbers: TMU-T104–06, TMU-T105–06, TMU-T106–03, and 105TMU-CIT–01–3); and “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. This manuscript was edited by Wallace Academic Editing.

Availability of data and materials
All the data related to the study are included within the article and the supplemental material.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Institutional Review Board of Chang Gung Medical Foundation. Animal research was approved by the Institutional Animal Care and Use Committee of Taipei Medical University.
Consent for publication
No applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. 2Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. 3School of Life Sciences and Technology, Taipei Medical University, Taipei 11031, Taiwan. 4Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan. 5College of Medicine, Chang Gung University, Taoyuan 33022, Taiwan. 6Department of Pathology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan. 7School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. 8Institute of Clinical Medicine, College of Medicine, National Yang Ming University, Taipei 11221, Taiwan. 9Division of Medical Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan. 10School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 33382, Taiwan. 11Division of Internal Medicine, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan. 12International PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. 13Centre for Reproductive Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. 14Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan. 15Comprehensive Cancer Center of Taipei Medical University, Taipei 11031, Taiwan.

Received: 3 June 2019 Accepted: 10 October 2019

Published online: 26 November 2019

References
1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev. 2016; 25:16–27.
2. El-Sebaii HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–73.e1.
3. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19:223–38.
4. Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol. 2015;110:836–44.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:78–90.
7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
8. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs. 2005;16:797–803.
9. Kenet KF, Tai WT, Hsu CY, Huang JW, Liu CY, Chen PJ, et al. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. Eur J Med Chem. 2012;55:220–7.
10. Gao L, Shao C, Lv F, Wang X, Tang Y. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report. Cell Oncol (Dordr). 2018;41:85–91.
11. Gao L, Wang X, Tang Y, Huang S, Hu CA, Tang Y. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017;36:58.
12. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
13. Guo Z, Li L-Q, Jiang J-H, Ou C, Zeng L-X, Xiang B-D. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol. 2014;20:2098–106.
14. Chang TS, Wu YC, Chi CC, Su WC, Chang PJ, Lee KY, et al. Activation of IL-6/IGF1R confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression. Clin Cancer Res. 2015;21:201–10.
15. Mauer J, Dennis JL, Bruning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 2015;36:92–101.
16. Rokavec M, Wu L, Luo J-L. IGF1R-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell. 2012;45:777–89.
17. Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludewig G, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology. 2014;147:393–404.
18. Soresi M, Gianntrapi L, D’Antona F, Frenna AM, La Spada E, Terranova A, et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006;12:2563–8.
19. Babaie Y, Hervig R, Greber B, Brink TC, Warkewitz G, Groth D, et al. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells. 2007;25:500–10.
20. Ben-Porath I, Thomson MW, Carey VI, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40:499–507.
21. Hattori N, Nishino K, Kyo YG, Hattori N, Ohgane J, Tanaka S, et al. Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells. J Biol Chem. 2004;279:10636–9.
22. Wang L, Guo ZY, Zhang R, Xin B, Chen R, Zhao J, et al. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Cancerogene. 2013;14:1773–81.
23. Zeineddine D, Hammond AA, Mortada M, Beof H. The Oct4 protein: more than a magic stemness marker. Am J Stem Cells. 2014;3:74–82.
24. Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R, et al. A role for OCT4 in tumor immunity of drug-resistant prostate cancer cells. Genes Cancer. 2010;1:908–16.
25. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gromotty PA, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene. 2012;31:4898–911.
26. Murakami S, Nominoya W, Sakamoto E, Shibata T, Akiyama H, Tashiro F, SRY and OCT4 are required for the acquisition of cancer stem cell-like properties and are potential differentiation therapy targets. Stem Cells. 2013;31:2716–23.
27. Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modifiers, modifiers and mediators in cancer etiology and progression. Nat Rev Genet. 2016;17:284–99.
28. Hochadelinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 2005;121:465–78.
29. Scarola M, Comiso E, Pascolo R, Chiardia R, Marion RM, Schneider C, et al. Epigenetic silencing of Oct4 by a complex containing SUV39H1 and Oct4 pseudogene IncRNA. Nat Commun. 2015;6:7631.
30. Lopez-Berthon H, Lai B, Li A, Caplan M, Guererro-Cazares H, Eberhart CG, et al. DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2. Oncogene. 2015;34:4994–4004.
31. Kuks M, Merkel A, Heath S, Queros AC, Schuyler RP, Castellano G, et al. Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nat Genet. 2015;47:746–56.
32. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, et al. The Human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999;27:2291–8.
33. Nagai M, Nakamura A, Makino R, Mitamura K, Expression of DNA (cytosine)-methyltransferases (DNMTs) in hepatocellular carcinomas. Hepatol Res. 2003; 26:186–91.
34. Oh BK, Kim H, Park Hj, Shim YH, Choi J, Park C, et al. DNA methyltransferase expression and DNA methylation in hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med. 2007;20:665–73.
35. Lee S, Lee HJ, Kim JH, Lee HS, Jiang J, Kang GH, Aberrant Cpg island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 2003; 163:1371–8.
36. Park HY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH, et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology. 2007;131:1476–94.
37. Wang J, Wang Z, Fan YX, Si YQ, Wang JX. DNA methyltransferase 3b silencing affects locus-specific DNA methylation and inhibits proliferation, migration and invasion in human hepatocellular carcinoma SMMC-7721 and BEL-7402 cells. Oncol Lett. 2015;9:2499–506.

38. Siddiqui NN, Ul Haq A, Siddiqui OA, Khan R. DNA methyltransferase 1, 3a, and 3b expression in hepatitis C associated human hepatocellular carcinoma and their clinicopathological association. Tumour Biol. 2016;37:10497–97.

39. Lan T, Chang L, Wu Y, Yuan YF. IL-6 plays a crucial role in HBV infection. J Clin Transl Hepatol. 2013;3:271–6.

40. van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F, et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2013;329:74–83.

41. Zhang Q, Wang HY, Woetmann A, Odum N, Wasik MAJB. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood. 2006;108:1058–64.

42. Chen WC, Chen MF, Lin PY. Significance of DNMT3B in oral cancer. PLoS One. 2014;9:e89956.

43. Briacini C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytic cells. Hepatology. 2010;51:881–90.

44. Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, de Haar C, van der Woude CJ. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis. 2012;33:889–96.

45. Menyhart O, Nagy A, Gyory B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2018;5:181006.

46. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarti B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–58.

47. Kuck D, Gaulfield T, Lyko F, Medina-Franco JL. Nanomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther. 2010;9:3015–23.

48. Liu CC, Lin JH, Hsu TW, Su K, Li AF, Hsu HS, et al. IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation. Int J Cancer. 2015;136:547–59.

49. Foran E, Garrity-Park MM, Mureau C, Newell J, Smyrk TC, Limburg PJ, et al. Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. Mol Cancer Res. 2010;8:471–81.

50. Quan Z, He Y, Luo C, Xia Y, Zhao Y, Liu N, et al. Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b. Cell Signal. 2017;32:48–58.

51. Balakrishnan A, Guruprasad KP, Satyamoorthy K, Joshi MB. Interleukin-6 determines protein stabilization of DNA methyltransferases and alters DNA promoter methylation of genes associated with insulin signaling and angiogenesis. Lab Invest. 2018;98:1143–58.

52. Wang XQ, Qngkoe WM, Chen L, Yang ZF, Lu P, Chen KK, et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology. 2010;52:328–39.

53. Yin X, Li Y-W, Zhang B-H, Ren Z-G, Qiu S-J, Yi Y, et al. Coexpression of stemness factors Oct4 and Nanog predict liver resection. Ann Surg Oncol. 2012;19:2877–87.

54. Read SA, Douglas MW. Virus induced inflammation and cancer development. Cancer Lett. 2014;345:174–81.

55. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012;56:1004–14.

56. Unsal H, Yakicer C, Marcais C, Kew M, Volkmann M, Zentgraf H, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1994;91:822–6.

57. Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14.

58. Yu Z, Li Y, Fan H, Liu Z, Pestell RG. miRNAs regulate stem cell self-renewal and differentiation. Front Genet. 2012;3:191.

59. Guo X, Yu L, Zhang Z, Dai G, Gao T, Guo W. miR-335 negatively regulates osteosarcoma stem cell-like properties by targeting POU5F1. Cancer Cell Int. 2017;17:29.

60. Jia Y, Liu H, Zhuang Q, Xu S, Yang Z, Li J, et al. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep. 2012;27:1865–72.

61. Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci. 2012;57:1122–9.

62. Miller W, Holden J, George E, Stein K. NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia. Lancet Oncol. 2011;12:3526–7.

63. Liu J, Liu Y, Meng L, Liu K, Ji B. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep. 2017;38:899–907.

64. Nagaprasanthanya L, Vartak N, Awasthi S, Awasthi S, Singhal SS. Novel anti-cancer compounds for developing combinatorial therapies to target ankis-resistant tumors. Pharm Res. 2012;29:621–36.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.